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Hepatocellular carcinoma (HCC), the most common liver cancer, is an important leading cause of death 
worldwide. Neddylation is a post-translational modification involved in several processes such as cell growth, 
viability and development. Importantly, the neddylation pathway is upregulated in liver cancer and specifically 
enriched in patients with poor prognosis. Hu antigen R (HuR), is a RNA-binding protein that stabilizes target 
mRNAs involved in hepatocyte proliferation, differentiation and malignant transformation. And notably, HuR 
levels are highly representative in liver and colon cancer. A ground-breaking knowledge about HCC has been to 
identify that neddylation plays a role in HCC by regulating the liver oncogenic driver HuR. In addition, the 
neddylation inhibitor MLN4924 has shown antitumoral effects in vitro and in vivo in liver cancer, partly through 
HuR destabilization. Importantly, high levels of HuR made hepatoma cells more resistant to neddylation 
inhibition while low levels of HuR sensitized cells to the treatment, suggesting that the levels of HuR determine 
the druggability of the neddylation pathway in HCC. Overall, our findings highlight the impact that neddylation 
plays in liver cancer and open a completely new area of research, paving the way for novel therapeutical 
approaches. 
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Introduction 
Hepatocellular carcinoma (HCC) is the fifth most common 
cancer worldwide and the third leading cause of death by 
malignancy [1]. HCC is a very complex and heterogeneous 
pathology with multiple and distinct signaling pathways 
converging in the same malignant transformation [2].  
Hu antigen R (HuR) is the most ubiquitous member of the 
mammalian Hu/elav family of RNA-binding proteins (RBPs), 
that also includes the neuronal members HuB, HuC and HuD 
[3, 4]. HuR (also known as ELAVL1) has been described to 
stabilize ARE-containing mRNAs [5, 6] and to modulate their 
translation, both enhancing and inhibiting it [7]. In the 
cytoplasm, HuR can promote mRNA stabilization and 
upregulation or repression of mRNA translation [8, 9]. 
Many of the HuR-regulated mRNAs participate in the 
acquisition of cancer traits such as enhanced ability to 
proliferate, enhanced cell survival, elevation of local 
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angiogenesis, evasion of immune recognition, and invasion 
and metastasis [9, 10]. Many studies have examined the levels 
of HuR in different cancer types, finding them misregulated 
among others in breast, pancreatic, colon and ovarian cancer, 
constituting an important prognostic factor [8, 9]. HuR has also 
been found elevated in the liver of cirrhotic patients, together 
with a prominent increase of the cytosolic localization [11]. 
Also, HuR has been found highly expressed in the 
hepatocellular carcinoma (HCC)-derived SAMe-D cell line, in 
which it stabilizes HAUSP mRNA. HAUSP is an ubiquitin 
specific protease that stabilizes p53 in the cytosol inducing the 
cell cycle arrest and the apoptotic response [12]. 
In the liver, HuR plays a role in hepatocyte proliferation, 
differentiation and hepatocellular carcinoma transformation, 
participating in the switch from MAT II enzyme (expressed in 
fetal and proliferating liver and during malignant 
transformation) to MAT I/III (expressed in normal adult 
liver)[13]. In this case, HuR stabilizes MAT2A mRNA (that 
codifies for MAT II) whereas methyl-HuR destabilizes it. 
Through liver differentiation, the methyl-HuR/HuR ratio 
increases leading to the decrease of MAT2A mRNA. In the 
proliferating liver and during malignant transformation the 
process is the opposite. The modulation of the levels of MAT 
II and MATI/III regulates the abundance of S-
adenosylmethionine, which is critical for liver function [13]. 
In addition to this regulation, HuR nucleocytoplasmic 
shuttling is activated by AMPK in response to HGF during 
hepatocyte proliferation. The blockade of this translocation is 
able to abrogate cell cycle progression [14], as occurs in the 
Gnmt KO mice after partial hepatectomy, which present an 
impaired liver regeneration [15]. 
Moreover, HuR is able to regulate hepatic stellate cells 
activation and to raise the expression of proinflamatory and 
chemoattractant genes in a cholestatic liver injury model (bile 
duct ligation). In this way, HuR increases liver damage, 
oxidative stress, inflammation, macrophage infiltration and 
liver fibrosis development, enhancing the risk of HCC 
development [16]. Finally, both in HCC and colon cancer cells, 
together with patients, HuR is overexpressed through a novel 
mechanism based on Mdm2-mediated neddylation [17].  
Neddylation promotes timely stabilization of proteins with 
essential regulatory roles in an extensive variety of biological 
processes [18]. Through modification of cullins, Nedd8 
controls the activity of cullin-ring-ligases and subsequently 
the stability of multiple substrates. A misregulation in 
neddylation disturbs protein homeostasis, which is linked to 
malignant transformation [19]. We have previously identified 
and characterized multiple functions of neddylation in liver 
tumorigenesis [17, 20]. Indeed, we have established a significant 
increase in neddylation levels in human HCC, which is 
associated with faster tumor progression and with a signature 
of poor outcome [20]. Additionally, we have found that primary 
pathways for anticancer drug development including 
PI3K/Akt, LKB1 and HuR in the liver are new targets for 
neddylation, undoubtedly providing important insights into 
the regulatory mechanism of these oncogenic pathways. 
Importantly, neddylation controls the nuclear localization of 
HuR, protecting it from degradation and increasing its stability 
[17].  
Neddylation inhibition has been described as a potential 
treatment for HCC [20, 21]. Indeed, the treatment with the drug 
MLN4924 and the silencing of Nedd8 and NAE1 showed 
antitumoral effects inducing apoptosis and a metabolic 
reprogramming in liver cancer cells and the reduction of tumor 
progression in vivo in the Phb1 KO HCC mouse model. 
Importantly, the restoration of LKB1 and Akt expression was 
able to block the metabolic reprogramming and associated cell 
apoptosis induced by neddylation inhibition [20]. These data 
further support that both LKB1 and Akt destabilization 
partially drive the metabolic phenotype induced by lack of 
neddylation.  
In this work we have studied the role of HuR in the 
mediation of the apoptotic response induced by neddylation 
inhibiton in liver cancer cells. Regulating the expression of 
HuR using specific adenovirus and lentivirus we have been 
able to modulate the sensitivity to neddylation inhibition in 
HepG2 and BCLC3 hepatoma cell lines.  
These results support a cooperative association between 
HuR levels and neddylation inhibition and pave the way for 
novel and more personalized therapeutical approaches for 
HCC.  
Materials and Methods 
Cell lines  
In vitro experiments were performed using the following 
human hepatoma cell lines: BCLC3 human hepatoma cell line 
was previously characterized and provided by Dr. Jordi Bruix 
and Dr Loreto Boix (BCLC group. Hospital Clinic, Barcelona, 
Spain), and HepG2 cell line was obtained from American 
Type Culture Collection (Manassas, VA). 
Treatment of cell lines with MLN4924  
HepG2 and BCLC3 cell lines were treated with MLN4924 
at a dose of 3M and maintained for 48 and 72 hours. At the 
indicated times, cells were lysed and proteins were analyzed 
by Western blotting. MLN4924 was provided by Millennium 
Pharmaceuticals Inc. 
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In vitro silencing  
BCLC3 and HepG2 cell lines were transfected with 100 nM 
Nedd8 siRNA (Qiagen) using the Lipofectamine 2000 reagent 
(Invitrogen). Controls were transfected with an unrelated 
siRNA (Qiagen). Protein knockdown was confirmed by 
Western blotting.  
Viral infection  
For HuR knockdown, HepG2 and BCLC3 cell lines were 
treated with short-hairpin lentiviral particles against HuR. For 
HuR overexpression, adenoviral particles, (AdHuR), were 
added [30]. Importantly, 24 h after the infection the medium 
was changed.  
Protein isolation & western blotting  
Extraction of total protein from cultured cells has been 
described [28]. Four to twenty five μg of protein were 
electrophoresed on sodium dodecyl sulfate-polyacrylamide 
gels and transferred onto membranes. A description of the 
antibodies used is provided in Supplementary Table 1. 
RNA isolation and real-time polymerase chain reaction  
Total RNA was isolated using Trizol (Invitrogen, UK). One 
to two μg of total RNA was treated with DNAse (Promega, 
UK) and reverse transcribed into cDNA using M-MLV 
Reverse Transcriptase (Invitrogen, UK). Then, qPCR was 
performed using iQTM SYBR® Green Supermix (Bio-Rad) 
Figure 1. MLN4924 reduces HuR expression and induces apoptosis in hepatoma cells. (A) 
Western blot analysis using the indicated antibodies and (B) caspase 3 activity assays in total 
lysates from HepG2 and BCLC3 cell lines after 48 and 72 hours of MLN4924 3M treatment. 
*p<0.05; **p<0.01 MLN4924 vs control. Data are mean ± SD. 
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using the CFX ConnectTM RT-PCR Detection System (Bio-
Rad). Expression levels were normalized to the average level 
of α2-macroglobulin mRNA in each sample. The sequence of 
primers used for quantitative reverse-transcription polymerase 
chain reaction (qRT-PCR) analysis is described in 
Supplementary Table 2.  
Apoptosis measurement 
Caspase 3 activity was quantified on cell protein extracts by 
proteolytic cleavage of the fluorogenic substrate Ac-Asp-Glu-
Val-Asp-AFC (AFC = 7-Amino-4- trifluoromethyl coumarin) 
(Enzo BML-P409). Fluorescence was quantified with a 
SpectraMax M2 microplate reader (Molecular Devices, Palo 
Alto, CA, USA).  
Statistical analysis  
All experiments were performed in triplicate. Data are 
expressed as mean ± SD. Statistical significance was estimated 
with Student ́s t test. p value<0.05 was considered significant.  
Results  
Neddylation inhibition triggers an apoptotic response in 
liver cancer cells 
Previous studies reported that MLN4924 induced apoptosis 
in HepG2 and Huh7 cells [21]. Similarly, we found that NAE1 
inhibition suppressed cancer cell growth in HepG2 and 
BCLC3 cells as demonstrated by the appearance of PARP 
cleavage and an increase in caspase 3 activity (Fig. 1A-B). 
Decreased neddylation, measured as accumulation of Nedd8-
cullin conjugated levels, was accompanied with an 
accumulation of well-known CRL/CSF substrates such as p21, 
p27 and Mdm2 indicating efficient inactivation of NAE1 by 
MLN4924. 
Importantly, neddylation pathway inhibition using a 
specific Nedd8 siRNA (Fig. 2A) induced the same apoptotic 
Figure 2. Neddylation pathway specific knockdown induces 
apoptosis in liver cancer cells. HepG2 and BCLC3 cells were silenced 
with a specific Nedd8 siRNA for 48 hours. (A) Whole-cell lysates were 
analyzed by Western blotting using the indicated antibodies and (B) by 
caspase 3 activity assay. *p<0.05 siNedd8 vs control. Data are mean ± 
SD. 
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response in HepG2 and BCLC3 cell lines, as shown by caspase 
3 activity (Fig. 2B). 
Blocking neddylation reduces HuR levels in liver cancer 
cells  
Considering that MLN4924 exerts its effect by inactivating 
Nedd8 activating enzyme, we assessed the levels of the 
recently characterized protein target of neddylation deeply 
implicated in liver tumors, HuR. We hypothesized that NAE1 
inhibitor should induce HuR destabilization and reduction of 
its total levels. Indeed, a remarkable decrease in HuR was 
coupled with the apoptotic response detected in each cell line 
after MLN4924 treatment (Fig. 1A). Importantly, we did not 
observe any regulation at mRNA level (data not shown).  
Along with cell death, Nedd8 knockdown destabilized HuR 
protein (Fig. 2A), confirming a direct impact of this protein 
levels in the apoptosis mediated by neddylation blockage in 
liver tumor cells. 
These findings suggest that neddylation inhibition regulates 
key proteins for tumor survival like HuR, enhancing liver 
apoptosis. Moreover, these results indicate that elevated HuR 
levels in tumor cells exert a proliferative and antiapoptotic 
function and allowed us to hypothesize the role of this RNA 
binding protein in the MLN4924-induced apoptotic response. 
The druggability of the neddylation pathway in liver 
cancer cells is associated with the HuR-dependent 
apoptotic response 
We have recently described that HuR is a new target for 
neddylation and plays a central role in modulating a variety of 
Figure 3. HuR silencing makes cells more sensitive to MLN4924 treatment. HepG2 and BCLC3 
cells were infected with a specific HuR lentivirus and treated with MLN4924 (3μM) for the indicated 
times. (A) Whole-cell lysates were analyzed via Western blotting with the indicated antibodies and 
(B) by caspase 3 activity assay. *p<0.05 MLN4924 vs control. Data are mean ± SD. 
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complex physiological and pathological processes in the liver 
[16, 17]. We studied the role of HuR in MLN4924-mediated 
apoptosis in HepG2 and BCLC3 cells.  
First, a lentivirus-based intervention to reduce HuR 
expression levels (Fig. 3A) affected significantly cell death 
after MLN4924 treatment for 48 and 72 hours as shown by 
caspase 3 activity (Fig. 3B). Next, a more accentuated 
overexpression of HuR was achieved by infection with an 
adenoviral vector (AdHuR) (Fig. 4A). We tested whether 
increased HuR levels influenced MLN4924 sensitivity. At 72 
and 96 hours after transfection, HuR overexpression resulted 
in a significant reduction of caspase 3 activity after MLN4924 
treatment (Fig. 4B). Low levels of HuR made liver cancer cells 
more sensitive to the efficiency of the neddylation inhibitor 
MLN4924 while increasing its expression levels rendered 
cancer cells more resistant to the apoptotic response induced 
by the drug. 
HuR promotes mRNA stability and/or translation of several 
anti-apoptotic and proliferative proteins. The positive 
influence of HuR was due to the stabilization of a subset of 
mRNAs involved in cell survival. Hence, an increase in Bcl-
2, cyclin D1, prothymosin-alpha (PTMA) and X-linked 
inhibitor of apoptosis protein (XIAP) mRNA levels was 
detected in the hepatoma cells overexpressing HuR (Fig. 5A-
B).  
Moreover, no variations in CRLs substrates and 
proliferative pathways were detected after overexpression of 
Figure 4. HuR overexpression makes cells more resistant to MLN4924 treatment. HepG2 and BCLC3 
cells were infected with a specific HuR adenovirus and cultured with MLN4924 (3μM) for the indicated 
times. Whole-cell lysates were analyzed via Western blotting with the indicated antibodies (A) and for 
caspase 3 activity (B). *p>0.05 MLN4924 vs control. 
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HuR indicating that the prosurvival effect exerted by this RNA 
binding protein was independent of these mechanisms (Fig. 
3A, 4A).  
These results support a cooperative association between 
HuR levels and neddylation inhibition since reducing or 
increasing its expression results in a sensitivity modulation 
upon MLN4924 treatment. 
Discussion 
HCC is the most common liver cancer and the third leading 
cause of death by malignancy worldwide [1]. It is a poor 
prognosis cancer, since in most cases is detected at an 
advanced stage. Moreover, HCC is a very complex and 
heterogeneous pathology with multiple signaling pathways 
converging in the same malignant transformation [2]. It is 
phenotypically and genetically very heterogeneous and 
resistant to conventional chemotherapy [22]. For these reasons, 
its incidence is similar to its mortality. The development of the 
HCC is a multifactorial process, being the alcohol and virus 
the most common factors. But recently, obesity, diabetes type 
2 and NAFLD have been identified as risk factors for HCC 
development [23]. 
In spite of its high incidence and mortality HCC still 
remains poorly understood and no effective treatment has been 
yet identified. There are currently three drugs being used in 
patients: Sorafenib [24], a threonin-thyrosin kinase inhibitor, 
Sunitinib [25], a threonin-thyrosin kinase inhibitor and 
Figure 5. HuR overexpression induces antiapoptotic genes. Graphical 
representation of the mRNA expression (arbitrary units) of the indicated genes. 
(A) HepG2 and (B) BCLC3 cells treated with MLN4924 (3μM) for 96h. *p<0.05; 
**p<0.01 AdHur vs control. Data are mean ± SD. 
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Everolimus [26], which acts directly through mTOR. These 
drugs only give patients four or five more months of life. The 
only effective treatments nowadays are liver transplantation 
and resection.  
In order to improve HCC clinical treatment it is necessary 
to unravel new mechanisms that regulate at different levels the 
variety of pathways implicated in its development. 
In this work we propose neddylation, a new post-
traslational modification, as a global regulator of HCC 
progression. Cellular protein homeostasis is essential for 
multiple physiological systems, and imbalance in this 
equilibrium can lead to cell death, uncontrolled cellular 
proliferation and cancer development. The Nedd8 pathway is 
essential for cell growth through the activation of CRLs and 
the degradation of their substrates, which are essential in 
cancer development [18]. 
Importantly, in human liver samples a significant 
correlation among global levels of neddylation, NAE1 protein 
expression and the poorest prognosis of HCC was detected. 
These data underpin that Nedd8 regulate the homeostasis of 
proteins essential for liver cancer. Significantly Akt, master 
kinase for cancer development [27], LKB1 recently associated 
with liver tumors [12, 28] and HuR, frequently overexpressed in 
HCC correlating with its malignancy [17], were regulated by 
neddylation in human hepatoma cells.  
Taking into account the central role of HuR in hepatocyte 
proliferation, differentiation and malignant transformation and 
its tightly regulated levels, this new mechanism involving the 
post-translational modification Nedd8 that explains the 
overexpression of HuR in HCC and colon cancer can offer 
important advantages for the treatment of liver cancer.  
The potential antitumoral activity for the NAE1 inhibitor 
MLN4924 [29], which is in phase II clinical trials for the 
treatment of leukaemia, has been shown in human colon, lung 
and liver tumor xenograft models in immunocompromised 
mice [20, 21, 29]. Importantly, neddylation inhibition drastically 
reduced the levels of HuR in liver cancer cells and in a HCC 
mouse model characterized by high neddylation levels. This 
protein deregulation was accompanied with an apoptotic 
response and the regression of the tumor.  
Notably, the overexpression of HuR made liver cancer cells 
more resistant to the death induced by MLN4924. In the same 
way, HuR silencing increased the susceptibility of cancer cells 
to the apoptotic response upon neddylation inhibition. These 
results suggest a role for HuR as an important sensor and 
regulator of the susceptibility of liver cancer cells to 
MLN4924 treatment. 
Overall, our findings highlight the relevance of increased 
levels of HuR for hepatocyte proliferation, survival and 
malignant transformation. Importantly, we show that HuR is 
upregulated in HCC through neddylation, which is also highly 
representative in liver cancer and that its levels determine the 
druggability of the neddylation pathway in HCC. These data 
open new scenery for new therapeutic and personalized 
strategies for liver cancer treatment. 
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Table 1. Optimal Incubation Conditions, Concentration, and Supplier for Each Specific Antibody Analyzed by 
Western Blotting 
β-actin Sigma  1/5000 TBS-Tween (0.1%)-milk (5%) 
GAPDH Abcam  1/5000  TBS-Tween (0.1%)-milk (5%) 
HuR Santa Cruz Biotechnology 1/5000 TBS-Tween (0.1%)-milk (5%) 
Mdm2  Calbiochem 1/1000 TBS-Tween (0.1%)-milk (5%) 
Nedd8 Abcam  1/1000 TBS-Tween (0.1%)-milk (5%) 
p21 Santa Cruz Biotechnology 1/1000  TBS-Tween (0.1%)-milk (5%) 
p27 Santa Cruz Biotechnology 1/1000  TBS-Tween (0.1%)-milk (5%) 




Table 2. Sequence of primers used for RT-PCR analysis 
GENE NAME OFFICIAL SYMBOL  SEQUENCE 
B-cell lymphoma 2  Bcl2   Forward 5’-CTGCACCTGACGCCCTTCACC-3’  
Reverse 5’-CACATGACCCCACCGAACTCAAAGA-3' 
X-linked inhibitor of apoptosis XIAP Forward 5'-GGGGTTCAGTTTCAAGGACA-3' 
Reverse 5'-CGCCTTAGCTGCTCTTCAGT-3' 
Cyclin D1 Cyclin D1 Forward 5'-GCGCAGACCTTCGTTGCCCT-3' 
Reverse 5'-GCGCAGGCTTGACTCCAGCA-3' 
Prothymosin, alpha   PTMA   Forward 5’-CAGCTTTATCGCCAGCGTCC-3’ 
Reverse 5’-AGTCCTTGGTGGTGATTTCG-3 
Beta-2-microglobulin   B2M   Forward 5’-TCTCTGTCTGGATGATGACGTGAG-3’ 
Reverse 5’-TAGCTGTGCTCGCGCTACT-3 
 
 
 
